Results 21 to 30 of about 11,456 (188)

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes [PDF]

, 2023
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit with a large inter-individual variation. The underlying mechanisms for
Heerspink, Hiddo J L, Stevens, Jasper, Bokkers, Reinoud P H; id_orcid, Heerspink, Hiddo J.L., Heeres, Andre, Sjoukje van der Hoek, Slart, Riemer H J A, Hiddo J. L. Heerspink, van der Hoek, Sjoukje, Stevens, Jasper; id_orcid, Bokkers, Reinoud P H, Douwe J. Mulder, Ton Visser, Philip H. Elsinga, Elsinga, Philip H, Mulder, Douwe J., Elsinga, Philip H., Antoon T. M. Willemsen, Willemsen, Antoon T M, Jasper Stevens, Visser, Ton, Andre Heeres, Bokkers, Reinoud P.H., Riemer H. J. A. Slart, Willemsen, Antoon T.M., Reinoud P. H. Bokkers, Mulder, Douwe J; id_orcid, Mulder, Douwe J, Slart, Riemer H.J.A.   +28 more
core   +1 more source

Canagliflozin for weight loss in non-diabetic individuals [PDF]

, 2023
Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is primarily used as an anti-diabetic medication, but recent evidence suggests its potential role in promoting weight loss in individuals without diabetes.
Tousif, Meirajuddin, Akhtar, Maria, Oza, Yugam   +2 more
core   +1 more source

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats

SVU - International Journal of Medical Sciences, 2023
Background: Sodium-glucose Cotransporter-2 inhibitors [SGLT2Is] are new antidiabetic group. Canagliflozin is the first member in this drug class approved for management of patient with type 2 diabetes (T2DM), that affects reabsorption of glucose from ...
Manal M.G. Mourad*, Fares E.M Ali , Sabah A. Fadel, Reham A.M. Ellisy   +3 more
doaj   +1 more source

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan

Journal of Diabetes Investigation, 2022
Aims/Introduction The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial has shown the effects of canagliflozin on preventing clinically important kidney outcomes in patients with type 2 diabetes ...
Takashi Wada, Kazumi Mori‐Anai, Akiko Takahashi, Takahiro Matsui, Masaya Inagaki, Mitsutaka Iida, Ken Maruyama, Hidetaka Tsuda   +7 more
doaj   +1 more source

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Communications Biology, 2023
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response.
Amr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, Evangelia E. Tsakiridis, Elham Ahmadi, Jianhan Wu, Simon Wang, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Aruz Mesci, Stanley Liu, Tobias Berg, Jonathan L. Bramson, Gregory R. Steinberg, Theodoros Tsakiridis   +15 more
doaj   +1 more source

Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy

Frontiers in Immunology, 2022
Idiopathic membranous nephropathy is the main cause of chronic kidney disease (CKD). Studies have shown sodium–glucose co-transporter 2 (SGLT2) inhibitors significantly delay renal outcomes in patients with CKD, but the exact mechanism remains unknown ...
Xin Lv, Xin Lv, Xin Lv, Xin Lv, Jian Wang, Jian Wang, Jian Wang, Li Zhang, Li Zhang, Xian Shao, Xian Shao, Yao Lin, Yao Lin, Hongyan Liu, Hongyan Liu, Guangyang Ma, Guangyang Ma, Jing Li, Jing Li, Saijun Zhou, Saijun Zhou, Pei Yu, Pei Yu   +22 more
doaj   +1 more source

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Journal of Translational Medicine, 2019
Background The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with ...
Alex Ali Sayour, Sevil Korkmaz-Icöz, Sivakkanan Loganathan, Mihály Ruppert, Viktor Nabil Sayour, Attila Oláh, Kálmán Benke, Maik Brune, Rita Benkő, Eszter Mária Horváth, Matthias Karck, Béla Merkely, Tamás Radovits, Gábor Szabó   +13 more
doaj   +1 more source

Canagliflozin : something new for type 2 diabetes, but is it safe and efficacious? [PDF]

, 2014
Evaluation of Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and\ud safety of canagliflozin in Japanese patients with type 2 diabetes: a\ud randomized, double-blind, placebo-controlled, 12-week study.\ud Diabetes Obes Metab 2013.
McIntyre, Kerry, Doggrell, Sheila
core   +1 more source

Efficient Route to Canagliflozin via Anhydroketopyranose

, 2022
The development of an efficient route for the synthesis of Canagliflozin is reported. The anhydroketopyranose intermediate was isolated as a novel intermediate, which was used to prepare Canagliflozin API in high ...
Debjit Basu (1687720), Kiran Kumar Singarapu (1457089), Rakeshwar Bandichhor (739508), Rakeshwar Bandichhor, Debjit Basu, Aaseef Mohammad, Kiran Kumar Singarapu, Ratnamala Annapragada (12511852), Aaseef Mohammad (4694713), Ratnamala Annapragada, Ch.V. A. Sasikala (12511849), Ch.V. A. Sasikala   +11 more
core   +1 more source

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus [PDF]

, 2015
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2 ...
Susan Cornell, Curtis Triplitt
core   +1 more source